Related Experiment Video

Updated: May 11, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Combination of daidzein, hemin and bms182874 halts the progression of diabetes-induced experimental nephropathy

Taruna Katyal1, Arun Garg, R D Budhiraja

  • 1Indo Soviet Friendship College of pharmacy, Moga, Punjab, India. tarunakatyal@gmail.com

Endocrine, Metabolic & Immune Disorders Drug Targets
|May 25, 2013
PubMed

Insights

This study shows that a combination of daidzein, hemin, and BMS182874 significantly improves kidney function in diabetic nephropathy (DN) rats. This therapy enhances nitric oxide levels and offers renoprotection.

Area of Science:

  • Nephrology
  • Pharmacology
  • Endocrinology

Background:

  • Diabetic nephropathy (DN) is a major complication of diabetes, leading to kidney damage.
  • Current treatments for DN have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the combined therapeutic effects of daidzein, hemin, and BMS182874 on diabetic nephropathy in a rat model.
  • To elucidate the underlying mechanisms of this combined therapy's renoprotective action.

Main Methods:

  • Diabetic nephropathy was induced in Wistar rats using streptozotocin.
  • Renal function was assessed through biochemical markers (serum creatinine, BUN, proteinuria) and histopathology.
  • The effects of individual drugs and their combinations were compared, including the use of L-NAME to assess nitric oxide involvement.

Main Results:

  • The combination of daidzein, hemin, and BMS182874 significantly improved all measured renal parameters in DN rats compared to single-drug or two-drug combinations.
  • This combination therapy led to reduced serum creatinine, BUN, and proteinuria, and improved renal collagen content and oxidative stress markers.
  • The renoprotective effect was partially abolished by L-NAME, indicating a role for nitric oxide.

Conclusions:

  • Daidzein and hemin combination may increase renal nitric oxide by reducing caveolin expression.
  • BMS182874 provides renoprotection by inhibiting the RAAS system and restoring nitric oxide synthesis.
  • This combined therapy offers a promising approach for managing diabetic nephropathy, with potential mechanistic insights into its efficacy.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...